Vikram Sudarsan, Engrail Therapeutics CEO
Mid-stage neuroscience startup Engrail raises $157M
Engrail Therapeutics is riding a neuroscience tailwind.
Last year as it set out to raise its latest fundraising round, the startup originally targeted $100 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.